Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Jasper Therapeutics Inc.

In a report released yesterday, Justin Zelin from BTIG reiterated a Buy rating on Jasper Therapeutics, with a price target of $7.00. The company’s ...

BTIG Keeps Their Buy Rating on Jasper Therapeutics (JSPR)

William Blair analyst Matt Phipps maintained a Hold rating on Jasper Therapeutics yesterday. The company’s shares closed yesterday at $1.78. Phipps...

Market Cap	$49.81M	P/E Ratio	N/A
52W High	$26.05	52W Low	$1.56
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	43.4%	52W Position	0.6%
Overall Score	39	Value Score	60
Quality Score	--	Technical Score	18

EPS Current Est	$-4.94	EPS Next Est	$-2.75
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	JSPR	$1.70	-3.41%	300.23K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	JSPR	$1.70	-3.4%	300.23K
3
4
5
6

JSPR

JSPR

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Jasper Therapeutics Inc. Data in Excel

Get Jasper Therapeutics Inc. Data in Excel